Is VIVS or VRAX more undervalued in 2026?

CirclFi compares VivoSim Labs, Inc. (VIVS) and Virax Biolabs Group Limited (VRAX) using 13 institutional-grade valuation models. VIVS has a Quality of Company score of 4.5/10 while VRAX scores 1.6/10.

Which is a better buy — VIVS or VRAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VIVS and VRAX valuations compare?

VIVS at $1.31 and VRAX at $0.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VIVS vs VRAX Valuation Comparison 2026 — Intrinsic Value Analysis

VIVS

Biotechnology

VivoSim Labs, Inc.

Quality

4.5

out of 10

Value Trap

LOW

Price

$1.31

Last close

Models

10/13

Active

VRAX

Biotechnology

Virax Biolabs Group Limited

Quality

1.6

out of 10

Value Trap

SAFE

Price

$0.21

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	VIVS Fair Value	VIVS Upside	VRAX Fair Value	VRAX Upside
Bayesian DCF	Intrinsic	$1.03	-21.2%	$0.06	-73.5%
Earnings Power Value	Intrinsic	$3.09	+114.7%	—	—
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$1.84	+40.5%	$0.28	+125.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VIVS vs VRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VIVS vs VRAX — Which Stock Is More Undervalued?

VIVS scores higher with a 4.5/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VivoSim Labs, Inc. (VIVS) and Virax Biolabs Group Limited (VRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VIVS currently trades at $1.31 with a QOC of 4.5/10, while VRAX trades at $0.21 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).